Get all your news in one place.
100's of premium titles.
One app.
Start reading
Fortune
Fortune
Sheryl Estrada

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

(Credit: Courtesy of Eli Lilly and Company)

Good morning.

As a CFO, making investments to bring real innovation to the marketplace can position the company for long-term growth. But when it comes to innovation in health care, like combating obesity, the implications can impact the lives of millions of people. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.